Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Pilot Study is to investigate the safety, side effects, and benefits of
tumor- infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab
is a type of immunotherapy - a drug that is used to boost the ability of the immune system to
fight cancer, infection, and other diseases.
The primary endpoints of this pilot trial will be the safety and feasibility of the treatment
regimens.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Bristol-Myers Squibb Iovance Biotherapeutics, Inc. Prometheus Inc.